Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Aug 6, 2024Blog | Member News, Healthcare

Vertex’s non-opioid painkiller gets FDA priority review date

DepositPhotos

New England Council member, Vertex, has developed a new drug, suzetrigine, a non-opioid experimental painkiller that has been given priority review by the U.S. Food and Drug Administration.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of January 30, 2025, meaning that it intends to decide about the medication on or before that date. Suzetrigine is a medication that targets certain sodium channels and thereby prevents pain signals from going to the brain. In January 2024, Vertex said the drug did not show any serious side effects and would seek broad approval for treating moderate-to-severe acute pain, which impacts over 80 million people in the U.S. per year.

“The FDA’s granting of a priority review further reinforces the high unmet need in treating acute pain, and the filing brings us one step closer to our objective of filling the gap between medicines with good tolerability but limited efficacy and opioid medicines with therapeutic efficacy but known risks, including addictive potential,” said Vertex executive VP and chief regulatory and quality officer Nia Tatsis in the company’s announcement.

The New England Council commends Vertex for its commitment to targeting acute pain in this innovative manner.

Read more in the Boston Business Journal.

Council Related News
Read Article Blog | Member News, Technology & Innovation

Amazon celebrates opening of $300M Charlton robotics fulfillment center

Read Article Blog | Member News, Energy & Environment

Eversource brings “Main Streets” event to help bring Connecticut businesses affordable energy efficiency upgrades

Read Article Blog | Member News, Higher Education

University of New England joins global entrepreneurship network

Read Article Blog | Member News, Higher Education

Framingham State University museum receives largest donation in 50-year history

Read Article Blog | Member News, Healthcare

Point32Health hires new CEO

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit